adibendan

a pyridyl-pyrrolo-benzimidazole

Also Known As:

7,7-dimethyl-2-(4-pyridyl)-6,7-dihydro-3H,5H pyrrolo (2,3-f)benz-imidazol-6-one; BM 14.478; BM 14478; BM-14478; Pyrrolo(2,3-f)benzimidazol-6(1H)-one, 5,7-dihydro-7,7-dimethyl-2-(4-pyridinyl)-

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Alkaloids: 5398
  - Indole Alkaloids: 200
    - Oxindoles: 118
      - adibendan: 3
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Indole Alkaloids: 200
        Oxindoles: 118
        adibendan: 3
    - Indolizines: 3
      - Indolizidines: 2
        Indole Alkaloids: 200
        Oxindoles: 118
        adibendan: 3

Related Diseases

Heart Failure

06/01/1990 - "10 patients with chronic heart failure NYHA II-IV (mean age 67 +/- 5 years) got Adibendan i.v. A maximum increase in cardiac index from 2.3 +/- 0.5 to 3.2 +/- 0.5 l/min.m2 (p less than 0.001) was seen after a cumulative dosage of 0.916 +/- 0.571 mg at a time interval of 107 +/- 43 min after injection of the first dosage of 0.125 mg. There was a pronounced increase in stroke volume index from 30 +/- 6 to 40 +/- 8 ml/m2 (p less than 0.01). "
08/01/1989 - "Acute hemodynamic effects of adibendan, a new phosphodiesterase inhibitor, for severe congestive heart failure."
07/01/1991 - "The present study was performed to compare the effects of the new positive inotropic phosphodiesterase III inhibitors pimobendan, adibendan, and saterinone on the isometric force of contraction in electrically driven ventricular trabeculae carneae isolated from explanted failing (end-stage myocardial failure) with those from nonfailing (prospective organ donors) human hearts. "

Related Drugs and Biologics

1.	Type 3 Cyclic Nucleotide Phosphodiesterases
2.	saterinone
3.	pimobendan
4.	Phosphodiesterase Inhibitors